Setraline safe and effective for depression in ACS patients

Pfizer's selective serotonin reuptake inhibitor Zoloft (sertraline)has become the first antidepressant shown in a published clinical trial to be safe and effective for the treatment of major depression in patients suffering from acute coronary syndromes. Major depressive disorder occurs in 15%-23% of patients with acute coronary syndromes and constitutes an independent risk factor for morbidity and mortality, according to the authors, who have published the results of the 369-patient study in the Journal of the American Medical Association (August 14).